(Arg)9-SH2 superbinder: a novel promising anticancer therapy to melanoma by blocking phosphotyrosine signaling
Melanoma is a malignant tumor with high misdiagnosis rate and poor prognosis. The bio-targeted therapy is a prevailing method in the treatment of melanoma; however, the accompanying drug resistance is inevitable. SH2 superbinder, a triple-mutant of the Src Homology 2 (SH2) domain, shows potent antitumor ability by replacing natural SH2-containing proteins and blocking multiple pY-based signaling pathways. Polyarginine (Arg)9, a powerful vector for intracellular delivery of large molecules, could transport therapeutic agents across cell membrane. The purpose of this study is to construct (Arg)9-SH2 superbinder and investigate its effects on melanoma cells, expecting to provide potential new approaches for anti-cancer therapy and overcoming the unavoidable drug resistance of single-targeted antitumor agents.
(Arg)9 and SH2 superbinder were fused to form (Arg)9-SH2 superbinder via genetic engineering. Pull down assay was performed to identify that (Arg)9-SH2 superbinder could capture a wide variety of pY proteins. Immunofluorescence was used to detect the efficiency of (Arg)9-SH2 superbinder entering cells. The proliferation ability was assessed by MTT and colony formation assay. In addition, wound healing and transwell assay were performed to evaluate migration of B16F10, A375 and A375/DDP cells. Moreover, apoptosis caused by (Arg)9-SH2 superbinder was analyzed by flow cytometry-based Annexin V/PI. Furthermore, western blot revealed that (Arg)9-SH2 superbinder influenced some pY-related signaling pathways. Finally, B16F10 xenograft model was established to confirm whether (Arg)9-SH2 superbinder could restrain the growth of tumor.
Our data showed that (Arg)9-SH2 superbinder had the ability to enter melanoma cells effectively and displayed strong affinities for various pY proteins. Furthermore, (Arg)9-SH2 superbinder could repress proliferation, migration and induce apoptosis of melanoma cells by regulating PI3K/AKT, MAPK/ERK and JAK/STAT signaling pathways. Importantly, (Arg)9-SH2 superbinder could significantly inhibit the growth of tumor in mice.
(Arg)9-SH2 superbinder exhibited high affinities for pY proteins, which showed effective anticancer ability by replacing SH2-containing proteins and blocking diverse pY-based pathways. The remarkable ability of (Arg)9-SH2 superbinder to inhibit cancer cell proliferation and tumor growth might open the door to explore the SH2 superbinder as a therapeutic agent for cancer treatment.
KeywordsMelanoma Phosphorylated tyrosine proteins SH2 superbinder Cell penetrating peptides Drug resistance
- (Arg)9-SH2 superbinder
(Arg)9-GST-Src SH2 TrM
Cell penetrating peptides
- SH2 TrM
SH2 superbinder, the Src Homology 2 (SH2) domain with the triple-mutant Thr8Val/Cys10Ala/Lys15Leu
Melanoma, which can be cured by surgery in the early stage but the prognosis is poor, accounts for about 80% of skin cancer deaths. This is largely because metastatic malignancy is refractory to conventional therapies [1, 2, 3, 4]. Gene mutations, mostly BRAF mutations, are present in over half of all human melanomas. Although patients with BRAF-mutant are highly sensitive to small molecule inhibitors, like Vemurafenib and Dabrafenib, most patients display partial responses to clinical treatment, which can eventually worsen conditions or cause death due to drug resistance within 6 to 12 months [5, 6, 7]. Moreover, patients that lack gene mutations have few effective therapeutic methods. These patients are associated with unique risk factors, pathophysiologic, clinical, and prognostic features that differ from those related to BRAF tumors . Thus, it is necessary and urgent to address the problems of drug resistance to inhibitors with BRAF-mutant and lacking appropriate therapies for patients without specific mutations.
Src Homology 2 (SH2) domains specifically recognize phosphorylated tyrosine and mediate cell signal transduction [9, 10]. The “superbinder” SH2 domain, with triple-point mutants Thr8Val/Cys10Ala/Lys15Leu, abbreviated SH2 superbinder, which could bind pY-containing peptides with much stronger affinity than natural SH2 domains or traditional anti-pY antibody (4G10) [11, 12]. Conventional drugs are generally directed against a single gene or protein and most of melanoma patients develop drug resistance eventually . SH2 superbinder, strongly binding with diverse pY sites to block related signal transduction pathways, can recognize other sites instead, even if mutation alters the pY site [14, 15]. Therefore, SH2 superbinder can achieve the purpose of killing cancer cells . These advantages might resolve problems of drug resistance due to gene mutation and lack of suitable targeting drugs described above. However, it is urgent to settle the problem of transporting SH2 superbinder across cell membrane barriers.
Cell penetrating peptides (CPPs), having ability to translocate across the plasma membranes, are confined to short sequences of less than 20 amino acids . CPPs have several advantages over conventional techniques on cellular delivery because they are efficient for a variety of cells, and have a potential therapeutic application . Nona-arginine (Arg)9, as one kind of CPPs, has been applied efficaciously to translocate across the cell membrane and deliver large cargo molecules such as peptides, proteins, and oligonucleotides into cells with no severe side effects, which has a prospect of wide application and a development potential in drug delivery [19, 20].
(Arg)9-SH2 superbinder (referred as (Arg)9-GST SH2 TrM) was conducted by genetic engineering approach. The results validated that (Arg)9-SH2 superbinder had strong ability to translocate into cells and played a role in melanoma cells by binding with various pY proteins. Furthermore, (Arg)9-SH2 superbinder could suppress proliferation and migration of melanoma cells. Meanwhile, apoptosis caused by (Arg)9-SH2 superbinder was observed. Additionally, PI3K/AKT, MAPK/ERK and JAK/STAT pathways were also affected by (Arg)9-SH2 superbinder. Moreover, (Arg)9-SH2 superbinder could inhibit the growth of tumor in vivo. Above all, (Arg)9-SH2 superbinder, which could translocate into cells efficaciously and provide a novel anticancer method for melanoma via capturing multiple pY-containing proteins, might be a potent candidate in the targeted therapy of melanoma.
Construction, expression and purification of GST fusion proteins
Genes encoding the human wild type and triple-mutant Src SH2 domains, from the pEGFP-C3-Src SH2 Wt/TrM plasmids, were subcloned into the pGEX-4 T3 vector for expressing GST-Src SH2 Wt/TrM proteins. Based on pGEX-4 T3-alone or pGEX-4 T3- Src-SH2 Wt/TrM, recombinant plasmids were constructed for expressing GST-(Arg)9, GST-Src-Wt/TrM-(Arg)9. Wt represented Wild type. Amino acid sequences and primers of all used constructs were listed in Additional file 1: Table S1 and Additional file 2: Table S2 of supplementary materials. As shown in Additional file 1: Table S1, although nona-arginines were put at the end of C-terminus of GST or GST-Src-SH2 Wt/TrM, we termed them as (Arg)9-GST or (Arg)9-GST-Src-SH2 Wt/TrM.
All amplified products were gel purified using the Gel Band Purification Kit (Beijing ComWin Biotech). The backbone was digested with BamHI (cat. # R3136V) and NotI (cat. # R3189V) in 37 °C for 2 h and the purified PCR products were reacted with the linearized pGEX-4 T3 vector at 37 °C for 30 min. The experiment is using the One Step Cloning Kit (Vazyme, Nanjing), according to the principle of homologous recombination. E.coli BL21 containing the expression plasmid was grown in LB broth with 100 μg/ml ampicillin at 37 °C. The expression of GST fusion protein was induced by the addition of isopropyl β-D-thiogalactoside (0.5 mM final concentration), and then incubated at 20 °C for 18 h. The lysis buffer of protein contains 20 mM Tris-HCl (pH 7.0), 50 mM NaCl, 0.5 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM cocktail, and 1 mM PMSF. GST fusion proteins were purified from bacterial cell lysates by glutathione-agarose beads. After sonication, cell lysates were cleared by centrifugation at 9500 rpm for 30 min, prior to mixing with glutathione-agarose beads. After rotating at 4 °C for 3 h, proteins could be eluted and collected. The protein concentration in the cell homogenates was quantified with BCA Protein Assay Kit. Immediately prior to their use in biological assays, protein purity was verified by SDS-PAGE using Coomassie brilliant blue staining intensity.
Cell lines and cell culture
B16F10 melanoma cells (no metastasis variant mouse melanoma), A375 (BRAF mutation) were purchased from the American Type Culture Collection (ATCC, Manassas, VA). The cisplatin (DDP)-resistant subline A375/DDP was established with continuous exposure of the parental A375 cells to increasing concentrations of cisplatin, ranging from 2 nM to 4 μM for about 6 months. The drug-resistant cells were maintained in DMEM containing 4 μM cisplatin. All cells were cultured in DMEM medium supplemented with 10% FBS and 100 U/mL penicillin- streptomycin and were maintained in a humid atmosphere with 5% CO2 at 37 °C.
Glutathione s-transferase pull down assay and western blot
For GST pull down assay, GST fusion proteins were expressed in E. coli BL21 (DE3). Cells were treated with phosphatase inhibitor sodium pervanadate (0.5 mM) for 10 min at 37 °C before harvesting. Then, cells were lysed in ice-cold lysis buffer (0.5% NP-40, 50 mM Hepes (pH 7.4), 1 mM magnesium chloride, 150 mM KCl, and the complete protease inhibitor cocktail). For immunoprecipitation and western blot (immunoblot), cells were lysed on ice in lysis buffer (1% NP-40, 50 Mm Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 10% glycerol, and the complete protease inhibitor cocktail). The supernatant was gathered after centrifugation at 12,000 g for 15 min. Protein A/G agarose (Thermo Fisher) and Glutathione Sepharose beads (GE Healthcare) were used for the immunoprecipitation and GST pull down assays, respectively. Protein concentrations were quantified by BCA method. The proteins were separated by a 10% SDS-polyacrylamide gel and eleco-transferred onto PVDF membranes (Millipore), which were incubated in 5% skim milk for 1 h at room temperature. Primary antibodies against EGFR(CST#4267), Grb2(CST#3972), pERK1/2(CST#4370), pSTAT3(CST#4113), pAKT(CST#4060), AKT(CST#9272), ERK1/2(CST#4695), STAT3(CST#4904), pY antibody (Abcam EPR16871), GAPDH(CST#5174), Bax(ABclonal#A12009) and Bcl2(ABclonal#A11025) were diluted at 1:1000 and then incubated with the membranes overnight at 4 °C. Membranes were washed three times for 10 min and incubated with a 1:5000 dilution of HRP-conjugated anti-mouse or anti-rabbit antibodies. Blots were washed with TBST three times and developed with the ECL system; the membranes were exposed to ChemiDoc MP Imager (BIO-RAD). The band densities were normalized relative to the relevant GAPDH with Image J software.
1 × 104 cells were seeded in a 12-well plate and cultured for 24 h. Cells were incubated with proteins with different time and concentrations. After washing with cold washing buffer, cells were then fixed in 4% formaldehyde at room temperature for 1 h, and then were permeabilized with 0.5% Triton X-100 for 20 min. After rinsing in PBS, cells were treated with rhodamine phalloidin for 30 min and then incubated with DAPI for 5 min at RT. Samples were imaged by a fluorescence microscope (Olympus, Japan). The images were analyzed by Image J software.
Cells collected in the logarithmic phase were plated into 96-well plates (3–5 × 103 cells/well). On the following day, add GST fusion proteins into the cell culture medium. After incubating for different time, 10 μL of 5 g/L MTT solutions (Sigma) were added into each well and incubated for 4 h, and then incubated with 100 μL DMSO for another 15 min. The optical absorbance was measured at the wavelength of 570 nm. Different treatment time and concentrations have been shown in the figure legends.
Cells collected in the logarithmic phase were plated into 96-well plates (5 × 103 cells/well). On the following day, add GST fusion proteins into cell culture medium with different concentrations. After incubating for various time, 10 μl CCK-8 solution (Dojindo) was added into each well and incubated for 1-4 h. The optical absorbance was measured at the wavelength of 450 nm.
Colony formation assay
Cells were trypsinized and plated in 6-well plates (100 cells/well), incubated with GST fusion proteins and counted 14 days after seeding. The colonies were subsequently fixed with 4% formaldehyde and stained with 0.01% crystal violet for 10 min.
Wound healing assay
Cells were seeded into six-well plates (5 × 105 cells/well). Wounds were then created using the 200 μL pipette tips. The scratched cells were removed by PBS for three times. Cells were then cultured for 16 h incubated in the presence or absence of (Arg)9-GST SH2 TrM. Microscopic images were taken with a digital camera at different time points.
2 × 104 cells were plated in 200 μL DMEM containing 2% FBS in the upper chamber. The lower chamber was filled with 500 μL completed medium containing 10%FBS. (Arg)9-GST SH2 TrM or (Arg)9-GST were added to the upper chamber and cells were allowed to migrate for 16 h at 37 °C with 5% CO2. Cells were fixed with 4% formaldehyde for 15 min at room temperature. Then, cells on the upper chamber were moved with a cotton swab. After washing the chambers with ddH2O, cells remained on the bottom of the lower chamber were stained with 0.1% crystal violet. The migrated clones were photographed under a microscope. The cell numbers were counted at three different areas.
Cells were sedimented by centrifugation, resuspended and fixed in 100 μl binding buffer. Cell density in the cell suspension was adjusted to 2 × 103cells/μl. Subsequently, 5 μl Annexin V-FITC was added to the cell suspension followed by gently vortexing and incubation for 10 min at room temperature in the dark. Thereafter, the cell suspension was incubated with 5 μl Propidiumiodide. All details need to refer to the instructions of kit (Tianjin Sungene Biotech). Cells were analyzed immediately using a FACS flow cytometer (FACS BD Biosciences, Germany) for Annexin V-FITC and Propidiumiodide binding. Dot plots and histograms were analyzed by Flowjo software.
TdT-UTP nick end labeling (TUNEL) assays were performed with one-step TUNEL apoptosis assay kit produced by Beyotime Institute of Biotechnology according to the manufacturer’s instructions. The FITC-labeled TUNEL-positive cells were imaged under a fluorescent microscope (Olympus, Japan). The cells with green fluorescence were defined as apoptotic cells. And images were analyzed by Image J software.
Xenograft model was established on C57Bl/6 mice (Animal Center of Tongji Medical College, Wuhan), 4–6 weeks old, weighing approximately 18-22 g. All studies involving animals were performed following the National Guides for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Tongji Medical College, Huazhong University of Science and Technology.
A suspension of 1 × 106 B16F10 cells (in 100 μl PBS) was subcutaneously injected into the right flank each mouse. After the development of an easily palpable tumor (7–10 days, approximately 5 mm in diameter). Tumor size was measured by using a caliper every 3 days and was calculated by using the following formula: tumor volume = 1/2(width)2 × length. Mice were divided into control group (B16F10 cells and PBS injected) and the experimental group (B16F10 cells and (Arg)9-GST SH2 TrM treated), n = 3 per group. Animals were euthanized when tumor size reached the ethical end point.
Preparation of PBMCs
Peripheral blood obtained from healthy C57Bl/6 mice was anticoagulated with heparin. PBMC were isolated by Ficoll (Germany) density gradient centrifugation of peripheral venous blood. Cells were washed three times and resuspended in DMEM medium supplemented with 1 mM sodium pyruvate, 1% nonessential amino acids and vitamins, 2 mM L-glutamine, 100 U/ml penicillin-streptomycin and 10% FBS.
The Student’s test was used to test for statistical significance of the differences between the different group parameters. P values of less than 0.05 were considered statistically significant.
Construction, expression and purification of GST fusion proteins
(Arg)9, (Arg)9-SH2 Wt/TrM, and SH2 Wt/TrM-alone (without nona-Arg) were subcloned into the pGEX-4 T3 backbone, respectively. The PCR product of SH2 Wt/TrM was 327 bp and the pGEX-4 T3-(Arg)9-SH2 Wt/TrM was 5295 bp. DNA gel electrophoresis and sequencing were utilized to confirm the successful construction of pGEX-4 T3-(Arg)9-SH2 Wt/TrM (Additional file 3: Figure S1a). Coomassie staining image showed that (Arg)9-GST SH2 Wt/TrM and (Arg)9-GST were expressed and glutathione-agarose beads were used to purify the expressed proteins (Additional file 3: Figure S1b). The molecular weight of (Arg)9-GST, (Arg)9-GST SH2 Wt/TrM, and GST SH2 Wt/TrM are about 26 kDa, 36 kDa, and 35 kDa, respectively.
(Arg)9-GST SH2 TrM could effectively bind with pY proteins
As SH2 domain can specifically recognize and bind to pY residues, SH2-containing proteins play a vital role in the pY-based signaling transduction . (Arg)9-GST SH2 TrM exhibits strong binding ability with pY proteins in cells, therefore, it may competitively displace the natural SH2-containing proteins and block a number of pY-based signaling pathways in cells.
(Arg)9-GST SH2 TrM could efficiently penetrate into melanoma cells
(Arg)9-GST SH2 TrM attenuated proliferation of melanoma cells
Targeting tyrosine kinases that can drive tumorigenesis is an effective strategy in molecular targeted therapy [22, 23]. EGFR family members are associated with many epithelial cancers [24, 25]. Due to its strong binding ability with pY-containing proteins, (Arg)9-GST SH2 TrM may decrease the tyrosine phosphorylation level of proteins derived from EGFR and act as an inhibitor of EGFR signaling and EGF-dependent cell growth. Moreover, Grb2, a critical adaptor protein in EGFR signaling , was found to bind less to EGFR after cells treated with (Arg)9-GST SH2 TrM (Fig. 4b). This indicated that (Arg)9-GST SH2 TrM effectively inhibited the EGF-dependent pathways, likely by competing for binding to the pY sites on the EGFR. Both MAPK/ERK and PI3K/AKT pathways are critical downstream pathways in the proliferation of cancer cells [27, 28, 29]. (Arg)9-GST SH2 TrM drastically reduced the phosphorylation of ERK and AKT(Fig. 4c), which are the downstream kinases of the EGFR signaling pathways . The results of A375 and A375/DDP cells were similar to B16F10 cells, and (Arg)9-GST SH2 TrM reduced the phosphorylation of ERK and AKT (Additional file 7: Figure S5a). These results proved that (Arg)9-GST SH2 TrM blocked the EGFR signal pathway and the downstream PI3K/AKT and MAPK/ERK signaling pathways in the proliferation of melanoma cells.
(Arg)9-GST SH2 TrM inhibited the migration of melanoma cells
(Arg)9-GST SH2 TrM induced apoptosis of B16F10 cells
It is known that Bax and Bcl2 play a pivotal role in the regulation process of apoptosis [31, 32]. The results showed that Bax was increased and Bcl-2 was decreased after treating with (Arg)9-GST SH2 TrM, enhancing that (Arg)9-GST SH2 TrM could promote apoptosis in B16F10 cells (Fig. 6b). JAK/STAT signaling pathway is involved in cell cycle progression and apoptosis [33, 34]. STAT3 was detected to understand the mechanism of apoptosis caused by (Arg)9-GST SH2 TrM. The pSTAT3 level was declined after treated with (Arg)9-GST SH2 TrM (Fig. 6c). As shown in Additional file 7: Figure S5b, the phosphorylation of STAT3 also decreased in the A375 and A375/DDP cells. These data revealed that (Arg)9-GST SH2 TrM might lead to melanoma cell death progression via blocking JAK/STAT signal pathway.
(Arg)9-GST SH2 TrM suppressed the growth of B16F10 cells on tumor-bearing mice
Undoubtedly, (Arg)9-GST-SH2 TrM protein must subject to the proteolysis in the bloodstream. To investigate its stability in blood, (Arg)9-GST-SH2 TrM protein was added into the dish with normal mouse serum (Abbkine, China) and the dish was gently shaken under 37 °C to mimic the condition of bloodstream. As shown in Fig. 7e, degradation of (Arg)9-GST SH2 TrM in the serum was checked by Western Blot with anti-GST antibody, and the fusion protein almost degraded at the time point of 4 h. At the same time, the stability of (Arg)9-GST-SH2 TrM protein in the lysated tumor tissue from B16F10 Xenograft mice was checked. The total level of GST-fused protein gradually increased from 1 h to 4 h, but (Arg)9-GST-SH2 TrM protein was observed to obviously degrade at the time point of 4 h (Fig. 7f). Furthermore, the phosphorylation level of tyrosine proteins in the lysated tumor tissue was examined by Western Blot with anti-pY antibody. The phosphorylation level of tyrosine proteins in the lysated tumor tissue from B16F10 Xenograft mice drastically decreased at 4 h after the injection of (Arg)9-GST-SH2 TrM (Fig. 7g), which indicated that (Arg)9-GST-SH2 TrM protein significantly blocked the pY-based signaling pathways by the strong binding with pY proteins in the tumor cells. All above data demonstrated that (Arg)9-GST-SH2 TrM protein exhibited excellent anti-tumor functions in spite of the proteolysis in vivo.
Patients, with BRAF (V600) in 40–60% of melanomas, can be successfully cured with selective inhibitors, bringing about significant prolongation of progression free survival and overall survival [35, 36]. Although BRAF inhibitors are effective treatment methods, drug resistance is inevitable, and high drug prices increase the burden on patients [37, 38, 39]. Meanwhile, the remaining 50–60% of patients are BRAF wild type and they do not benefit from treatment with BRAF inhibitors. A number of other mutations are present in these patients, such as NRAS, MEK1/2 and atypical (non-V600) BRAF mutations . Treatment of this subset of patients without a BRAFV600 mutation is a challenging problem.
EGF, an extracellular signal factor, can activate downstream Ras, by binding with the EGFR, and then phosphorylate Raf, decreasing Ras-GTPase activity. The EGF-dependent signal pathways are closely related with tumorigenesis . BRAF, an important member of Raf family, is the downstream effector of RAS. Protein tyrosine phosphorylation plays an essential role in the development and progression of cancer. Aberrant tyrosine phosphorylation is associated with cancer [41, 42]; Carcinogenic cells tend to exhibit abnormal high levels of phosphorylated tyrosine [43, 44]. Previous studies have proved that the inactivation of MAPK/ERK signaling pathways can regulate migration of HEK293T cells . The tight combination of SH2 superbinder and EGFR could block the activation of downstream signaling pathways . Similarly, our results substantiated that levels of pAKT, pERK1/2 and pSTAT3 were reduced by (Arg)9-SH2 superbinder via blocking the EGFR signaling pathway. Remarkably, the effects of (Arg)9-SH2 superbinder on pathways described above were involved in the regulation of cell apoptosis. There are a large number of members in Bcl-2 family involved in regulation of apoptosis, such as Bcl-2, Bcl-X1, Bcl-w, Bax, Bad, Bak, Bcl-xs, Mc1–1 et al. Bcl-2 and Bax, two most popular members of this family, were chosen to be examined in this study. The results indicated pro-apoptotic protein Bax increased and anti-apoptosis protein Bcl-2 declined in B16F10 cells after (Arg)9-SH2 superbinder incubation. Of course, it needs further investigations to check whether other members in Bcl-2 family mediate the process of (Arg)9-SH2 superbinder-induced apoptosis in future.
In addition, the powerful vector (Arg)9, for the intracellular delivery of conjugated large molecules, was applied efficaciously to translocate across the cell membrane and transport SH2 superbinder into the cytoplasm or nucleus of B16F10 cells. The results showed that fluorescence intensity of cells incubated with (Arg)9-GST SH2 TrM was higher than that of (Arg)9-GST because of the strong affinity between (Arg)9-GST SH2 TrM and pY-containing proteins in cells. Indeed, cell penetrating peptides inevitably have some toxicity effect on the cells. The MTT data in our work showed that (Arg)9-GST protein exhibited remarkably low toxicity, which is consistent with previous reports [45, 46]. In brief, (Arg)9 overcame the challenge of transporting therapeutic agents across cell membrane which showed a great value of application in biomedical system. Furthermore, we isolated the peripheral blood mononuclear cells(PBMCs) from mice and evaluated the penetration and toxicity effect of (Arg)9 fused proteins on PBMCs. As shown in Additional file 8: Figure S6a, the level of pY was very low in PBMCs as the non-cancerous cells. (Arg)9-GST-SH2 TrM protein could enter into PBMCs, but the green signal was very weak (Additional file 8: Figure S6b). Indeed, (Arg)9-GST-SH2 TrM protein caused some toxicity effect on PBMCs according to the CCK-8 data (Additional file 9: Figure S7), but it was moderate as (Arg)9-GST-SH2 TrM protein specifically recognizing and binding to pY residues, whereas the level of pY residues was verified to be very low in PBMCs.
These findings suggested that (Arg)9-SH2 superbinder could play a significant role in the progression of cell proliferation, migration and apoptosis. Importantly, these data implied that (Arg)9-SH2 superbinder, targeting multiple pY proteins, might be a useful anticancer therapy to address the difficulties of resistance and provide a novel effective way for melanoma.
In summary, it is the first time to combine (Arg)9 with SH2 superbinder to form a drug delivery system. The findings indicated (Arg)9-SH2 superbinder had potent antitumor ability by targeting various pY proteins and blocking diverse pY-based signaling pathways. The results verified that (Arg)9-SH2 superbinder could suppress proliferation, migration, and induce apoptosis of melanoma cells via regulating the activity of PI3K/AKT, MAPK/ERK and JAK/STAT signal pathways. (Arg)9-SH2 superbinder had the potential to act as a promising therapy for melanoma and displayed a prospective value of application.
This work was supported by Wuhan Youth Chenguang Program of Science and Technology Foundation (2016070204010100); the Fundamental Research Funds for the Central Universities (HUST: 2016YXMS201, 2015YGYL010); the National Natural Science Foundation of China (Nos. 31571431, 31771541); the Natural Science Foundation of Hubei Province of China (2016CFA053); and the Undergraduate Training Programs for Innovation and Entrepreneurship (HUST: jcyxy1705).
Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
ADL, HX, and YNG conducted the experiments; ZFL and DNL participated in the data analysis. XC, HX and ADL designed the experiments and drafted the manuscript. CV made the constructs of SH2 Wt and TrM. SL polished the manuscript and gave some useful advice. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All studies involving animals were performed following the National Guides for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Tongji Medical College, Huazhong University of Science and Technology.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 28.Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007;67:2497–507.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer. 2005;103:1265–73.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.